One of the most recent studies published in this field describes co-delivery of siRNA against triple-negative breast cancer oncogene IKBKE (Inhibitor of nuclear factor kappa-B kinase subunit epsilon) and cabazitaxel in nanocomplex modified with hyaluronic acid-targeting cancer cells. The gene discussed is IKBKE; the disease is cancer.